LUND, Sweden, Feb. 24, 2020 /PRNewswire/ -- BioInvent International AB (OMXS: BINV) will issue its interim report for the fourth quarter 2019 on Thursday February 27 at 7.30 a.m. CET, followed by an audiocast with teleconference at 8.30 a.m. CET, hosted by Martin Welschof, CEO and members of the management team. The presentation will be held in English.
To participate, please call any of the following phone numbers from:
BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. Two preclinical programs in solid tumors are expected to have entered clinical trials by the end of 2020. The Company's validated, proprietary F.I.R.S.TTM technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
This information was brought to you by Cision http://news.cision.com
The following files are available for download: